SWOG study shows neoadjuvant Keytruda helps prevent recurrence in high-risk melanoma

MD Anderson and CureVac collaborate to develop mRNA cancer vaccines

MD Anderson Cancer Center and CureVac N.V. are entering a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.

April 19, 2024

Vol.50 No.16

Clinical Roundup

UCLA study: Promising target for CAR T-cell therapy leads to potent antitumor responses against cutaneous and rare melanomas

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have built and demonstrated the potential efficacy of a new chimeric antigen receptor T-cell-based immunotherapy specifically designed to treat patients with cutaneous and rare subtypes of melanoma.

February 23, 2024

Vol.50 No.08

Drugs & Targets

MD Anderson, C-Biomex sign collaborative research agreement to co-develop CBT-001 radioligand therapy

MD Anderson Cancer Center and C-Biomex Ltd. have formed a strategic research collaboration agreement to co-develop CBT-001, a radioligand targeting the CA9 cancer biomarker.

February 16, 2024

Vol.50 No.07

In Brief

MD Anderson designated IAEA Collaborating Centre to focus on improving radiation, radiology and nuclear medicine

MD Anderson Cancer Center has signed an agreement with the International Atomic Energy Agency to become an IAEA Collaborating Centre.

February 02, 2024

Vol.50 No.05

Obituary

Cullen Taniguchi, radiation oncologist at MD Anderson, dies at 47

We unexpectedly lost a dear friend and colleague, Dr. Cullen Taniguchi, in mid-November. Dr. Taniguchi was an exceptional and compassionate clinician, brilliant scientist, and nurturing mentor. Above all, he was a dedicated and loving husband, father, son, and brother. We deeply mourn his loss, but we forever cherish the memories and indelible legacy that he leaves with us.

For cancer patients, traditional Medicare is better than Medicare Advantage

Now that the Medicare re-enrollment period has arrived (Oct. 15-Dec. 7), senior Americans are exposed to ubiquitous advertisements, phone calls, and other mechanisms to convince them to enroll in Medicare Advantage rather than traditional Medicare plans.

December 01, 2023

Vol.49 No.44

By Hagop M. Kantarjian and Mary Alma Welch

SWOG study shows neoadjuvant Keytruda helps prevent recurrence in high-risk melanoma

YOU MAY BE INTERESTED IN

MD Anderson and CureVac collaborate to develop mRNA cancer vaccines

UCLA study: Promising target for CAR T-cell therapy leads to potent antitumor responses against cutaneous and rare melanomas

MD Anderson, C-Biomex sign collaborative research agreement to co-develop CBT-001 radioligand therapy

MD Anderson designated IAEA Collaborating Centre to focus on improving radiation, radiology and nuclear medicine

Cullen Taniguchi, radiation oncologist at MD Anderson, dies at 47

For cancer patients, traditional Medicare is better than Medicare Advantage

Renew today!

Subscriber content

Login